Aarti Drugs Ltd Stock Price Today (NSE: AARTIDRUGS)
Fundamental Score
Aarti Drugs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aarti Drugs Ltd share price today is ₹367.70, down 0.97% on NSE/BSE as of 17 June 2026. Aarti Drugs Ltd (AARTIDRUGS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.80K (Cr). The 52-week high for AARTIDRUGS share price is ₹564.05 and the 52-week low is ₹318.95. At a P/E ratio of 19.07x, AARTIDRUGS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.69% and a debt-to-equity ratio of 0.39.
Aarti Drugs Ltd Share Price Chart — NSE/BSE Historical Performance
Aarti Drugs Ltd share price chart: 2.54% return over the past month. 52-week high ₹564.05, 52-week low ₹318.95.
Aarti Drugs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹379.50 | ₹383.00 | ₹378.00 | ₹380.80 | 69.00K (Cr) | |
| ₹385.90 | ₹391.05 | ₹379.00 | ₹382.90 | 78.86K (Cr) | |
| ₹388.75 | ₹393.75 | ₹377.50 | ₹380.40 | 1.14L (Cr) | |
| ₹390.90 | ₹390.90 | ₹390.90 | ₹390.90 | 0.00 (Cr) | |
| ₹394.00 | ₹398.90 | ₹390.00 | ₹390.90 | 98.44K (Cr) | |
| ₹398.40 | ₹407.20 | ₹390.80 | ₹394.40 | 3.47L (Cr) | |
| ₹393.00 | ₹399.00 | ₹388.60 | ₹394.45 | 1.37L (Cr) | |
| ₹379.35 | ₹393.45 | ₹373.50 | ₹389.95 | 1.99L (Cr) | |
| ₹384.95 | ₹384.95 | ₹378.30 | ₹380.40 | 51.47K (Cr) | |
| ₹375.30 | ₹386.40 | ₹370.10 | ₹381.65 | 1.81L (Cr) |
Aarti Drugs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹385.90 | ₹391.05 | ₹378.00 | ₹380.80 | -1.32% | |
| ₹376.30 | ₹407.20 | ₹356.10 | ₹380.40 | +1.09% | |
| ₹330.00 | ₹385.30 | ₹322.05 | ₹376.30 | +14.03% | |
| ₹350.00 | ₹364.80 | ₹318.95 | ₹319.75 | -8.64% | |
| ₹381.15 | ₹422.20 | ₹354.40 | ₹367.00 | -3.71% | |
| ₹412.55 | ₹417.70 | ₹362.25 | ₹381.05 | -7.64% | |
| ₹424.85 | ₹425.30 | ₹376.50 | ₹411.65 | -3.11% | |
| ₹491.10 | ₹534.00 | ₹423.50 | ₹424.85 | -13.49% | |
| ₹486.50 | ₹530.15 | ₹478.00 | ₹491.10 | +0.95% | |
| ₹469.65 | ₹534.55 | ₹465.00 | ₹486.50 | +3.59% | |
| ₹506.75 | ₹510.95 | ₹461.75 | ₹469.55 | -7.34% | |
| ₹459.95 | ₹564.05 | ₹456.65 | ₹506.75 | +10.18% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Aarti Drugs is a small-cap bet on the India pharma self-reliance theme, but execution risk is high.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Aarti Drugs' stock has shown mixed performance recently. It experienced a weekly gain of 6.49% between March 30 and April 2, closing at , outperforming the Sensex. This rise followed an upgrade of the company's investment rating from 'Strong Sell' to 'Sell' by MarketsMOJO. However, broader market weakness caused a 3.39% decline on March 30. The company has also been active in compliance-related announcements, including those related to re-lodgement of physical shares and the 'Saksham Niveshak' campaign.
CORE STORY (THE REAL GAME)
Aarti Drugs is being priced as a beneficiary of the Indian government's push for pharmaceutical self-reliance and API backward integration, rather than a pure-play generics exporter. The market is betting on capacity expansion and export growth.
- Recent rating upgrade suggests improving fundamentals.
- Credit rating reaffirmation indicates financial stability.
- Government initiatives support domestic pharma manufacturing.
- Successful ramp-up of new facilities.
- Significant order wins in API segment.
- Further policy support from the government.
- Small-cap stock with inherent liquidity risk.
- Decreasing promoter holdings.
- Intense competition and pricing pressure in generics.
FII increased holdings slightly (Δ 0.42%), while DII decreased slightly (Δ -0.04%). Promoter holdings decreased (Δ -0.5%).
The Indian pharmaceutical industry is undergoing a structural shift towards backward integration in APIs, supported by government policies.
Free Cash Flow 5Y is ₹164.97 Cr, indicating some profit converting to cash.
Aarti Drugs' future performance hinges on successful capacity expansion and backward integration. Expect volume-led growth and margin recovery in FY27.
Primary Thesis Risk
Failure to execute on capacity expansion and backward integration will kill the thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Aarti Drugs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aarti Drugs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AARTIDRUGS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 19.07 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (29.33%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Interest Coverage (7.77x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹164.97 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.72%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Weak Earnings Growth (4.46% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (4.03% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Aarti Drugs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Aarti Drugs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Aarti Drugs LtdAarti Drugs Ltd...Selected✓ AARTIDRUGS • 524348 | 50.2/100 | ₹367.70₹368 | ₹3796.48₹3796.48 | 19.07Average 19.1 Average | 12.69%Average 12.69% Average | 13.09%Average 13.09% Average | 0.39Excellent 0.4 Excellent | 4.03%Average 4.03% Average | 5.74%Good 5.74% Good | 0.24% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Aarti Drugs Ltd PE Ratio History
Historical price-to-earnings ratio for AARTIDRUGS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹18.35 | ₹411.65 | 22.4x |
| FY 2024 | ₹18.56 | ₹460.40 | 24.8x |
| FY 2023 | ₹17.97 | ₹489.20 | 27.2x |
| FY 2022 | ₹22.14 | ₹460.10 | 20.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Aarti Drugs Ltd Dividend History
Annual cash dividends paid by AARTIDRUGS — dividend yield 0.24%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹9.06 Cr |
| FY 2024 | ₹9.27 Cr |
| FY 2023 | ₹9.40 Cr |
| FY 2022 | ₹9.51 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Aarti Drugs Ltd Quarterly Performance
Latest quarterly metrics for AARTIDRUGS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
9.10%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
29.33%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
5.74%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
4.03%
Compounded annual net profit growth over 5 years
Aarti Drugs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AARTIDRUGS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Aarti Drugs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Aarti Drugs Ltd (AARTIDRUGS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Aarti Drugs Ltd
About AARTIDRUGS (Aarti Drugs Ltd)
Aarti Drugs Ltd is a prominent Indian pharmaceutical company engaged in the development, manufacturing, and global distribution of a diverse range of pharmaceutical products. With ...a strong emphasis on innovation and quality, the company operates through its subsidiaries, focusing on active pharmaceutical ingredients (APIs), crucial intermediates, specialized chemicals, and finished formulations. Their commitment to research and development is evident in their continuous efforts to enhance existing processes and introduce novel molecules, positioning them as a reliable partner for pharmaceutical companies worldwide. Aarti Drugs strives to uphold the highest standards of regulatory compliance and environmental responsibility in all aspects of their operations. The company's API portfolio encompasses a wide spectrum of therapeutic categories, including anti-inflammatory, antibiotic, and anti-infective agents. This extensive range allows Aarti Drugs to cater to the varied needs of their clientele, which includes generic pharmaceutical manufacturers and branded pharmaceutical companies. By vertically integrating their operations, from the production of key starting materials to the final API, Aarti Drugs maintains rigorous control over quality and supply chain efficiency. Their dedication to meeting stringent international quality standards has earned them a reputation for reliability and consistency in delivering high-quality products. Aarti Drugs extends its expertise beyond APIs, offering specialized chemical solutions tailored to the specific needs of its customers. Their commitment to providing comprehensive pharmaceutical solutions is further reinforced through their manufacturing and marketing of finished formulations. With a focus on affordability and accessibility, Aarti Drugs contributes to improving healthcare outcomes by offering cost-effective medications. Their dedication to innovation, quality, and customer satisfaction cements their position as a trusted and valuable player in the global pharmaceutical landscape.
Company Details
Key Leadership
Corporate Events
AARTIDRUGS Share Price: Frequently Asked Questions
What is the current share price of Aarti Drugs Ltd?
Aarti Drugs Ltd (AARTIDRUGS) trades at ₹367.70 on NSE and BSE. Market cap ₹3.80K (Cr). Educational data only.
What is the P/E ratio of Aarti Drugs Ltd?
Aarti Drugs Ltd has a P/E of 19.07x vs industry average 31.77x.
What is the Bull Run score for Aarti Drugs Ltd?
Aarti Drugs Ltd has a Bull Run score of 50.2/100 based on 25+ financial parameters.
Does Aarti Drugs Ltd pay dividends?
Aarti Drugs Ltd has a dividend yield of 0.24%. Past dividends don't guarantee future payments.
What is the ROE of Aarti Drugs Ltd?
Aarti Drugs Ltd has ROE of 12.69%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Aarti Drugs Ltd?
Aarti Drugs Ltd has debt-to-equity of 0.39.
Is Aarti Drugs Ltd a good investment?
Bull Run gives Aarti Drugs Ltd a score of 50.2/100. This is not investment advice — consult a SEBI-registered advisor.